510(k) device
Ablatherm Integrated Imaging
Edap Technomed, Inc. · High Intensity Ultrasound System For Prostate Tissue Ablation (PLP, Class II) · First FDA decision Nov 6, 2015, newest Nov 6, 2015Prostate cancer
Last checked: Nov 21, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
1
Naming "Ablatherm Integrated"
MAUDE reports
1
Brand "Ablatherm Integrated", since 2015
PubMed studies
0
Mentioning "Ablatherm Integrated"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Ablatherm Integrated Imaging
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
K153023 · Decided Nov 6, 2015 · 22 days after receipt
Device type: High Intensity Ultrasound System For Prostate Tissue Ablation (PLP) · GI, Urology & Nephrology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Cryosurgery Ablation for Prostate CancerNational analysisReview closedCAG-00031NUpdated Sep 14, 2026
- Laser Ablation of the ProstateLocal determinationIn effectL34090CGS Administrators, LLCUpdated Mar 25, 2026
- Transurethral Waterjet Ablation of the ProstateLocal determinationIn effectL38705Noridian Healthcare Solutions, LLCUpdated Feb 23, 2026
- Transurethral Waterjet Ablation of the ProstateLocal determinationIn effectL38549Palmetto GBAUpdated Oct 24, 2025
- Transurethral Waterjet Ablation of the ProstateLocal determinationIn effectL38682WPS Insurance CorporationUpdated Oct 21, 2025
- Magnetic Resonance Image Guided High Intensity Focused Ultrasound (MRgFUS) for TremorProposed local determinationProposedDL37421National Government Services, Inc.Updated Sep 18, 2025
- Transurethral Waterjet Ablation of the ProstateLocal determinationIn effectL38726First Coast Service Options, Inc.Updated Mar 14, 2025
- Transurethral Waterjet Ablation of the ProstateLocal determinationIn effectL38712Novitas Solutions, Inc.Updated Mar 14, 2025
Clinical trials
Device studies on ClinicalTrials.gov that name "Ablatherm Integrated", any status and sponsor, newest update first.
- Ablatherm Integrated Imaging High Intensity Focused Ultrasound for the Indication of Low Risk, Localized Prostate CancerStatus unknown
EDAP TMS S.A.Not on our public-company list
NCT00295802 · 141 participants · Start Apr 2006 · Primary completion Aug 2012
Device: Integrated Imaging High Intensity Focused Ultrasound; Endocare CRYOcare Cryosurgical and Galil Medical CRYO-HIT Systems (cryotherapy) · For: Prostate Cancer
Sites: Arcadia, California; Aurora, Colorado; Ocala, Florida · 15 sites in all
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Ablatherm Integrated", and for the whole product code for context.
This brand
1 reports: 0 malfunction, 1 injury, 0 death
Whole product code PLP
33 reports: 1 malfunction, 31 injury, 1 death
Newest reports for this brand
MW5068716 · Received Feb 17, 2017 · Event dated Dec 15, 2016
Device type: High Intensity Ultrasound System For Prostate Tissue Ablation (PLP)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Urinary Retention; Hematuria
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0049-2018 · Started Aug 14, 2017
Reason given: The US FDA has requested the optional energy treatment settings, "medium" and "low" (Software Protocols 02-Medium and 03-Low) be removed from all Ablatherm Integrated Imagining devices in the U.S. until supporting clinical data can be submitted and evaluated by FDA.
Cause as FDA categorized it: Other · Device type: High Intensity Ultrasound System For Prostate Tissue Ablation (PLP)
Published research
The most relevant PubMed records for "Ablatherm Integrated"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code PLP.
- TULSA-PRO SystemProfound Medical, Inc. · 510(k) 2023
- Focal One®Edap Technomed, Inc. · 510(k) 2025
- Exablate Model 2100V1Insightec, Ltd. · 510(k) 2023
- Tulsa Pro System (Pad-105)Profound Medical, Inc. · 510(k) 2024
- Ablatherm FusionEdap Technomed, Inc. · 510(k) 2017
- SonablateSonacare Medical, LLC · 510(k) 2016
- Sonablate 450Sonacare Medical, LLC · De Novo 2015
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.